IJAR - Indian Journal of Applied Research

Aritra Ghosh; Angana Datta; Saswati Sarkar; Mithilesh Haldar

Volume : VIII, Issue : IX, September - 2018

Efficacy and safety of epirubicin, oxaliplatin and capecitabine combination in treatment of non–resectable or advanced gastric carcinoma

Aritra Ghosh, Angana Datta, Saswati Sarkar, Mithilesh Haldar

Abstract :

Background– Assessment of clinical efficacy and safety of epirubicin, oxaliplatin and capecitabine (EOX) in the treatment of non–resectable or advanced gastric carcinoma. Methods– Total 50 patients were evaluated in the study for 425 days and they received epirubicin50 mg/m²and oxaliplatin 130 mg/m² as IV infusion on day one, capecitabine 1250 mg/m² in two divided doses orally from day 1to14. This cycle had been repetitively used every three weeks and given forsix cycles.

Results– Number of patients with complete response (CR), partial response (PR), progressive disease (PD) and stable disease (SD) were 4 (8%), 24 (48%), 10 (20%) and 12 (24%) respectively. Median progression free survival was 210 days. Haematological toxicities like anaemia, leukopenia, thrombocytopenia were most common. Alopecia, nausea–vomiting, anorexia, lethargy, neuropathy and diarrhoea were commonly occurred non–haematological toxicities.

Conclusion– EOX regimen showed good results in advanced gastric carcinoma both efficacy and safety wise. Larger study is required to establish the safety and efficacy of this regimen in our country.